Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: A population-based cohort study protocol

BMJ Open

Volumn 6, Issue 11, 2016, Pages

  Holbrook, Anne ^a,b   Dormuth, Colin ^c   Morrow, Richard ^c   Lee, Agnes ^c   Troyan, Sue ^b   Li, Guowei ^a   Pullenyegum, Eleanor ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

VASCULAR MEDICINE

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRITISH COLUMBIA; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EMBOLISM; FOLLOW UP; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PRESCRIPTION; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SYSTEMIC DISEASE; ADOLESCENT; AGED; BLEEDING; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; COMPLICATION; FACTUAL DATABASE; FEMALE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRITISH COLUMBIA; DATABASES, FACTUAL; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME; WARFARIN; YOUNG ADULT;

EID: 84999176962     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-013263     Document Type: Article

References (38)

1. Institute of Medicine (IOM). Initial national priorities for comparative effectiveness research. Washington (DC): The National Academies Press, 2009. http://www.nap.edu/openbook.php?record-id=12648
2. Chokshi DA, Avorn J, Kesselheim AS. Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. Health Aff (Millwood) 2010;29:1842-8.
3. Eikelboom J, Parekh A, Pogue J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
4. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
5. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
6. Weitz JI, Semchuk W, Turpie AGG, et al. Trends in prescribing oral anticoagulants in Canada, 2008-2014. Clin Ther 2015;37:2506-14.e4.
7. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e531S-e75S.
8. Allyn B. Blood-Thinner Pradaxa target of mass-claims suit. USA Today, August 19. 2012. http://www.usatoday.com/news/health/story/2012-08-19/pradaxa-blood-Thinnerlawsuit/57134628/1?csp=34news
9. Institute for Safe Medication Practices. QuarterWatch: Monitoring FDA MedWatch Reports. Anticoagulants the Leading Reported Drug Risk in 2011. 31 May 2012. http://www.ismp.org/quarterwatch/pdfs/2011Q4.pdf
10. Adverse Event Reporting System (AERS). Food and Drug Administration. 2011 (accessed 20 Aug 2012). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm
11. Wells G, Coyle D, Cameron C, et al. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Canadian Agency for Drugs and Technologies in Health, 2012.
12. Boehringer Ingelheim. Advisory committee briefing document. 2010:1-168. http://www.fda.gov/downloads/advisorycommittees//drugs//ucm226009.pdf (accessed 21 May 2011).
13. Sarich TC, Seltzer JH, Berkowitz SD, et al. Novel oral anticoagulants and reversal agents: considerations for clinical development. Am Heart J 2015;169:751-7.
14. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e152S-e84S.
15. Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: A systematic review and meta-Analysis of subgroups. Thrombosis 2013;2013:640723.
16. Appelboam R, Thomas EO. Warfarin and intracranial haemorrhage. Blood Rev 2009;23:1-9.
17. Mello MM, Goodman SN, Faden RR. Ethical considerations in studying drug safety-The Institute of Medicine report. N Engl J Med 2012;367:959-64.
18. DAgostinoJr RB, DAgostino Sr RB. Estimating treatment effects using observational data. J Am Med Assoc 2007;297:314-16.
19. GRACE Initiative. GRACE principles. Good research for comparative effectiveness observed. 10 April 2010. http://www.graceprinciples.org (accessed 25 May 2011).
20. Austin PC, Laupacis A. A tutorial on methods to estimating clinically and policy-meaningful measures of treatment effects in prospective observational studies: A review. Int J Biostat 2011;7:6.
21. https://www.popdata.bc.ca/home (accessed 16 May 2016).
22. Maura G, Blotiere PO, Bouillon K, et al. Comparison of the short-Term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: A French nationwide propensity-matched cohort study. Circulation 2015;132:1252-60.
23. Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: A retrospective cohort study. J Am Heart Assoc 2015;4:pii: e001798.
24. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study. Am J Med 2014;127:1172-8.e5.
25. Laliberte F, Cloutier M, Crivera C, et al. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: An observational study from a cohort of matched users. Clin Ther 2015;37:554-62.
26. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857.
27. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in Real world patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014;127:329-36.e4.
28. Raiford DS, Gutthann SP, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan Hospital automated database. Epidemiology 1996;7:101-4.
29. Arnason T, Wells PS, van Walraven C, et al. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 2006;118:253-62.
30. Juurlink D, Preyra C, Croxford R, et al. ICES investigative report-Canadian Institute for Health Information Discharge Abstract Database: A validation study. Toronto: Institute for Clinical Evaluative Sciences, 2006. http://www.ices.on.ca/file/cihi-dad-reabstractors-study.pdf
31. Levy AR, OBrien BJ, Sellors C, et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003;10:67-71.
32. Quan H, Li B, Saunders LD, et al. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008;43:1424-41.
33. Varadhan R, Weiss CO, Segal JB, et al. Evaluating health outcomes in the presence of competing risks: A review of statistical methods and clinical applications. Med Care 2010;48(6 Suppl):S96-S105.
34. Hernan MA, Hernandez-Diaz S. Beyond the intention-To-Treat in comparative effectiveness research. Clin Trials 2012;9:48-55.
35. Rose AJ, Ozonoff A, Henault LE, et al. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008;6:1647-54.
36. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 2014;12:1495-9.
37. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20: 512-22.
38. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60.